Abstract: A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial cells and endothelial cells.

Abstract: Described is a composition comprising a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2, and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.

Abstract: A method of conditioning/improving lung functions extracorporeally by treatment of a non-ischemic donor lung ex vivo with a cyclized compound of the amino acid sequence of formula X1-GQRETPEGAEAKPWY-X2 wherein X1 comprises an amino acid (sequence) with 1 to 4 members, comprising natural or unnatural amino acids, and X2 comprises one amino acid, selected from natural amino acids; and a pharmaceutical composition, comprising a peptide of formula I as defined in any one of claims 1 to 7, in a form, which is appropriate for spraying to obtain an aerosol for inhalation, or which is appropriate for the preparation of a spray to obtain an aerosol upon spraying, which is appropriate for inhalation.

Abstract: Described is a composition comprising a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2, and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.

Abstract: Cyclic peptide of formula I X1-GQRETPEGAEAKPWY-X2, wherein X1 comprises an amino acid (sequence), with 1 to 4 members, comprising natural and unnatural amino acids, and X2 comprises a natural amino acid, and wherein X1 comprises the N-terminal amino acid left in position 1, and X2 the C-terminal amino acid in the ultimate, right position, in the form of a lyophilisate without additives and/or stabilizers and its use.

Abstract: A cyclic polypeptide comprising at least six contiguous amino acids from the amino acid sequence SEQ ID NO:1 Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr for the treatment of autosomal recessive pseudohypoaldosteronism type 1 (PHA type1B) or for the restoration of the Na transport capacity of mutated loss-of-function ENaC.

Abstract: Described is a composition comprising a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2, and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and an inhibitor of viral neuraminidase.

Abstract: The present invention provides a method of treating and preventing altitude sickness, comprising the steps of: obtaining a peptide, wherein the peptide is 7-20 adjacent amino acids in length and comprises an amino acid sequence having a hexamer TX1EX2X3E, wherein X1, X2 and X3 can be any natural or unnatural amino acid, and wherein the peptide does not have tumor necrosis factor receptor binding activity, and wherein the peptide is cyclized; and administering to a patient having the pulmonary form of altitude sickness or being at risk of developing the pulmonary form of altitude sickness an effective amount of the peptide.

Abstract: Described is a composition comprising—a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and—an inhibitor of viral neuraminidase.

Abstract: Described herein are materials and methods for treating dyslipidemia in a mammalian subject in need thereof comprising administering a growth hormone-releasing hormone (GHRH) antagonist or variant thereof to the subject.

Abstract: A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial cells and endothelial cells.

Abstract: What is described is a peptide which consists of 7-20, especially 7-17, adjacent amino acids and comprises the hexamer TX1EX2X3E where X1, X2 and X3 may be any natural or unnatural amino acid, where the peptide does not have any TNF receptor binding activity and is cyclized, for use for the treatment and avoidance of the pulmonary form of altitude sickness.

Abstract: Described herein are materials and methods for treating dyslipidemia in a mammalian subject in need thereof comprising administering a growth hormone-releasing hormone (GHRH) antagonist or variant thereof to the subject.

Abstract: A peptide consisting of 7-17 amino acids and including the adjacent hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or non natural amino acid, wherein the peptide does not exhibit TNF-receptor-binding activity and is cyclic, for the treatment or prevention of vascular complications in diabetes patients.

Abstract: A method of conditioning/improving lung functions extracorporeally by treatment of a lung ex vivo with a cyclized compound of the amino acid sequence of formula X1-GQRETPEGAEAKPWY-X2??I wherein X1 comprises an amino acid (sequence) with 1 to 4 members, comprising natural or unnatural amino acids, and X2 comprises one amino acid, selected from natural amino acids; and a pharmaceutical composition, comprising a peptide of formula I as defined in any one of claims 1 to 7, in a form, which is appropriate for spraying to obtain an aerosol for inhalation, or which is appropriate for the preparation of a spray to obtain an aerosol upon spraying, which is appropriate for inhalation.

Abstract: What is described is a peptide which consists of 7-20, especially 7-17, adjacent amino acids and comprises the hexamer TX1EX2X3E where X1, X2 and X3 may be any natural or unnatural amino acid, where the peptide does not have any TNF receptor binding activity and is cyclized, for use for the treatment and avoidance of the pulmonary form of altitude sickness.

Abstract: A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial cells and endothelial cells.

Abstract: A cyclic organic compound which comprises 16 amino acids or 17 amino acids and has no carboxyl group C-terminally and/or no amino group N-terminally. Optionally, one of the amino acids is a nonnatural amino acid. The ring closure is formed between a side chain of one amino acid and the C-terminus of another amino acid, or the ring closure is effected with the aid of a nonnatural amino acid. A process for producing and using the compound for regulating vectorial ion channels, for treating diseases associated with the lung function and for treating oedemas is provided.

Abstract: Described is a composition comprising—a peptide which consists of 7-17 adjacent amino acids and comprises the hexamer TX1EX2X3E, where X1, X2 and X3 can be any natural or non-natural amino acid, and the peptide is cyclized and does not exhibit TNF receptor binding activity, and—an inhibitor of viral neuraminidase.

Abstract: A protein selected from the amino acid sequence of the region valine Val(91) to glycine Gly(121) of the mature human tumor necrosis factor, or a portion thereof, with the proviso that the protein comprises at least the amino acid sequence of the region lysine Lys(98) to glutamic acid Glu(116), with the cysteine Cys(101) being replaced by a glycine and an amide bond being formed between the amino group of the side chain of the lysine Lys(98) and the carboxyl group of the side chain of the glutamic acid Glu(116), which activates epithelial ion channels and improves the lung function and which can be used for the manufacture of medicaments for the treatment of diseases associated with the lung function, such as oedemas.